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Abstract
Objective—To study the sleep characteristics, pulmonary function, and their relationships in an
enzyme naive population of patients with mucopolysaccharidosis (MPS) II (Hunter syndrome).
Study design—The analyzed subjects (30 patients with MPS II with a median age of 9 years)
had been enrolled in an MPS II natural history study and a phase I/II enzyme replacement clinical
study in which they underwent standard polysomnography including spirometry and
plethysmography, if cooperative. Descriptive statistics and nonparametric correlation were
performed for demographic, sleep, and pulmonary function variables.
Results—Median apnea-hypopnea index (AHI) was 6.4, with obstructive sleep apnea (OSA)
observed in 27/30 subjects. Sleep architecture was characterized by diminished rapid-eye
movement (REM) sleep duration (median 13%), and decline in sleep efficiency and slow-wave
sleep (SWS) duration in older individuals. Oxygen desaturation below 90% occurred in 26/30
subjects, and hypoventilation above 50 torr occurred in 11/23 subjects with accurate end-tidal
carbon dioxide (ETCO2) recordings. Of fifteen subjects with reliable spirometry, median forced
expiratory volume in 1 second (FEV1) was below 80% predicted in 12/15 subjects. FEV1 in
percent-predicted (FEV1 %) was inversely related to AHI and increase from baseline ETCO2
(p=0.023, rs= −0.58), (p<0.001, rs= −0.82).
Conclusion—Sleep in MPS II is characterized by OSA, altered sleep architecture, and impaired
gas exchange. Sleep disruption is related to daytime pulmonary function, thus both systems should
be evaluated when sleep abnormalities are suspected.
© 2012 Mosby, Inc. All rights reserved.
Correspondence to: William I. Wooten, III, wwooten@med.unc.edu.
The other authors declare no conflicts of interest.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
J Pediatr. Author manuscript; available in PMC 2014 June 01.
Published in final edited form as:














Hunter syndrome; MPS; apnea; polysomnography; obstructive sleep apnea; hypoventilation;
pulmonary function; spirometry; plethysmography
The mucopolysaccharidoses (MPS) comprise a group of inherited disorders due to the
specific deficiency of a lysosomal enzyme and are clinically characterized by multiple organ
systems involvement and reduced life expectancy. Airway involvement and sleep problems
are common in most types of MPS, often involving altered sleep regulation and obstructive
sleep apnea (OSA) [1–5]. Early identification and treatment of sleep disorders is
recommended to prevent worsening of neurocognitive and cardiovascular function [6–8].
Mucopolysaccharidosis (MPS) II (Hunter syndrome), an X-linked recessive disorder, is
caused by the deficiency of iduronate sulfatase and presents with a wide spectrum of clinical
severity. The severe form of MPS II is characterized by mental retardation, communicating
hydrocephalus, hearing impairment, coarse facial features, hepatomegaly, obstructive airway
disease, cardiac dysfunction, joint stiffness, skeletal involvement and premature death. The
attenuated form of MPS II has similar albeit milder progression of somatic involvement
without the cognitive impairment, and these patients usually live into adulthood [7].
Although sleep is usually disrupted in MPS II, there are few studies describing sleep
characteristics in an enzyme naive population. Existing studies are limited by small sample
sizes, lack of standardized polysomnography and inclusion of other MPS types [1, 2, 9–11].
The natural history of sleep disorders in MPS II has not been described, which is an essential
prerequisite to evaluate the benefits of enzyme replacement therapy (ERT) that has become
standard of care. Airway obstruction is typical and often severe in MPS II, probably due
mostly to glycosaminoglycan (GAG) deposits within soft tissues of the upper and lower
respiratory tract. Restrictive lung disease, related to abnormal body shape, kyphoscoliosis
and altered chest wall dynamics, is also common. Thus the combination of restrictive and
obstructive disease may contribute to respiratory insufficiency, which further affects
hypoventilation during sleep [12, 13].
The aim of this cross-sectional study was to characterize baseline sleep patterns in patients
with MPS II naive to enzyme therapy, and to correlate the sleep disturbance with pulmonary
disease.
METHODS
We identified 30 patients with MPS II enrolled in research studies at the University of North
Carolina at Chapel Hill (UNC-CH) who underwent polysomnography and pulmonary
function testing. Two additional patients with tracheostomies were excluded. Diagnosis of
MPS II was based on deficient iduronate sulfatase activity in serum, plasma or leukocytes
and another normal sulfatase. Ten attenuated subjects were part of a phase I/II ERT clinical
trial of iduronidase with data from April to October 2001 [9]. The remaining 20 subjects
were studied as part of a natural history study sponsored by Transkaryotic Therapies, Inc.
with the initial clinical evaluation from November 2002 to March 2003. No subject had
received ERT at the time of clinical testing. The UNC-CH institutional review board
approved the original studies, and permission was granted by the UNC-CH institutional
review board to review this information without need to reconsent the subjects.
Demographic data and clinical history were obtained from the research and clinical records,
including age, height, weight, ethnicity, comorbid medical conditions, medications, use of
continuous positive airway pressure (CPAP), and previous airway surgery. Growth and body
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mass index (BMI) percentiles were calculated based on the United States Centers for
Disease Control and Prevention (CDC) guidelines [14].
Standard overnight polysomnography was performed in the clinical sleep laboratory of UNC
Hospitals, including nasal pressure and end-tidal carbon dioxide (ETCO2) measurements.
Subjects treated chronically with CPAP underwent split-night studies, and the portion of the
study using CPAP was excluded from analysis. Studies were interpreted by a certified sleep
physician using standard criteria consistent with the 2007 American Academy of Sleep
Medicine (AASM) scoring guidelines for pediatrics [15].
Spirometry was performed in accordance with American Thoracic Society standards,
typically within a few days of polysomnography [16]. Values of percent-predicted for
spirometry were expressed using reference values based on age, height and race according to
Hankinson, et al [17]. For three children less than 7 years of age able to perform spirometry,
percentiles were calculated per standard preschool reference equations published by Eigen,
et al [18]. Lung volumes were measured using body plethysmography and percentiles
calculated using standard reference equations [19].
Statistical analyses
Descriptive statistics were calculated for demographics, polysomnography, and pulmonary
function results. Because of small sample size and variability of results, data are reported
using median and range with nonparametric analyses. Two-tailed Spearman rank correlation
was performed to identify significant relationships between subject characteristics, sleep and
respiratory variables. Analysis was completed using GraphPad Prism version 5.0.
RESULTS
Subject demographic and clinical characteristics are summarized in Table I. All thirty
subjects were male, and all but three were Caucasian. In order to cooperate with required
testing, patients in the Phase I/II ERT clinical trial group were older and included only those
with the attenuated phenotype. In the entire population, airway surgery had been performed
in ten subjects. All of these surgeries had been performed more than two years prior to our
study, and the majority had been performed at other centers. Of those who did not have
airway surgery, 6 of 20 had history of other surgeries, including hernia repair, spinal fusion,
VP shunt placement, and repair of Arnold-Chiari malformation.
Significant comorbidities reported by subjects included asthma (4), gastroesophageal reflux
disease (2), aspiration (2), prematurity (2), and immunodeficiency (1). Daily use of
medications was reported by 22 of 30 subjects. Three subjects reported regular use of
medications for sleep, including zolpidem, melatonin and chloral hydrate. Other
medications, in order of frequency, included inhaled beta-agonists (10), non-steroidal anti-
inflammatory drugs (9), antihistamines (5), inhaled corticosteroids (4), over-the counter cold
remedies (3), angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker (3),
leukotriene modifier (3), proton pump inhibitor (3), antibiotics (3), nasal corticosteroids (2),
cromolyn (1), beta blocker (1), H2 blocker (1), carbamazepine (1), and baclofen (1).
Sleep parameters
Descriptive statistics for sleep parameters are presented in Table II. Sleep efficiency was
inversely related to age (Figure 1, B). Sleep was characterized by a variable number of
arousals, with more than 12 arousals per hour in 6/30 subjects. As REM sleep occurs
predominantly during the second half of the night and thus might affect comparison in
patients undergoing the split-night protocol with CPAP, we omitted four subjects on CPAP
for comparison of REM sleep. In the remaining 26 subjects, REM sleep duration was
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reduced compared with age expected norms, with a median of 11% (0.7–23%) in subjects
less than 10 years of age and 16% (11–24%) in subjects over age 10 [20]. Percentage of
slow-wave sleep (SWS) and stage I sleep were related to subject age (Figure 1, C and D).
The overall median AHI was 6.4 events per hour, with OSA identified in 27/30 subjects
based on AHI greater than 1.5. Moderate to severe OSA was present in 18/30 and eleven
subjects were severely affected with AHI greater than 10. Overall REM AHI was higher
than non-REM AHI, and 19 subjects had REM-related OSA based on REM AHI > 10. Of
the six patients with prior adenotonsillectomy as therapy for OSA, five had persistent OSA,
three with AHI greater than 10. Severity of OSA was not related to age (Table II) but was
directly related to BMI (p=0.038, rs=0.38).
Gas exchange abnormalities
The median minimum peripheral oxygen saturation (SpO2) was 81%, and decreased below
90% in 26/30 individuals. The median desaturation index (number of ≥3% desaturation
events per hour) was 6.4. Minimum SpO2 and desaturation index were correlated to AHI
(p=0.006, rs= −0.49), (p=0.002, rs=0.54). Serum bicarbonate while awake was normal in all
subjects, however ETCO2 increased above 50 torr in 11/23 subjects with accurate
measurements. Maximum ETCO2 was directly related to age (Table II and Figure 1, E) and
BMI (p=0.017, rs=0.49). The difference between maximum and initial ETCO2 was related to
AHI (p=0.004, rs=0.58).
Pulmonary function tests
Fifteen subjects were able to reproducibly perform spirometry, excluding two individuals
with a tracheostomy (Table II). Forced vital capacity (FVC) was less than 80% predicted in
11/15. Forced expiratory volume in 1 second (FEV1) was less than 80% predicted in 12/15,
with 10/15 below 65% predicted. FEV1/FVC was less than 0.8 in 7/15 subjects, indicating
obstructive pulmonary impairment. FVC and FEV1 in percent-predicted (FVC %, FEV1 %)
did not correlate with age but did correlate with BMI (p=0.007, rs=−0.66 for both).
Six of the 14 individuals who successfully performed plethysmography demonstrated
reduction in total lung capacity (TLC) below 80% predicted. Ratio of residual volume to
total lung capacity (RV/TLC) was 0.4 or greater in 11 of 14 subjects. RV/TLC was directly
related to age (Figure 1, F).
Relationships of polysomnography to pulmonary function
FEV1 % and RV/TLC were correlated to AHI (p=0.023, rs=−0.58), (p=0.019, rs= 0.62) and
minimum SpO2 (p=0.011, rs=0.63), (p=0.002, rs=−0.75). The six patients with RV/TLC
over 0.5 all had minimum SpO2 of 75% or lower. Degree of sleep related hypoventilation, as
measured by change from baseline ETCO2, was correlated with FEV1 % and RV/TLC
(Figure 2).
DISCUSSION
We observed that abnormal architecture, OSA, and gas exchange abnormalities characterize
sleep in patients with MPS II. Most individuals also had significant pulmonary impairment,
mostly a combination of obstructive and restrictive lung disease. Our results suggest that
pulmonary function may predict extent of OSA and hypoventilation, which has not
previously been described in MPS.
Sleep architecture in MPS II appears to be characterized by diminished REM sleep, along
with higher rates of decline in efficiency and SWS in older individuals than observed in the
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general population [20]. Although the etiology of the reduced duration of REM sleep in
patients with the severe phenotype of MPS II is unclear, this might reflect neurological
changes in REM sleep control mechanisms in the brainstem and diencephalon. Most likely,
alterations in sleep state control are largely secondary to OSA and associated poor sleep
quality. OSA was nearly universal in this population, often severe and persistent despite
prior surgical interventions.
Propensity for OSA is the consequence of numerous disease-related factors, including
deposits within the upper airway, glossoptosis, adenotonsillar hypertrophy, and impaired
respiratory control. Such high prevalence of OSA bears important clinical consequences in
this population because of its negative effects on neurocognitive function and cardiovascular
morbidity [6]. Further, despite the severity of OSA, patients exhibited relatively normal
arousal indices for age, possibly increasing risk for morbidity and mortality during sleep
[21].
Body habitus, GAG deposits in upper airway, and altered chest wall dynamics in MPS II
likely compound the sleep related problems. Similar to the general population, individuals
with the highest BMI were noted to have more severe OSA [22]. Diminished height,
scoliosis, and excess soft tissue adjacent to the lungs and airway may increase propensity for
airway collapse, especially during sleep, a time of relative airway hypotonia. As airway tone
is lowest during REM sleep, the high prevalence of REM-related OSA supports this notion.
Therefore, in spite of their abnormal growth, controlling BMI by limiting weight gain should
be attempted in patients with MPS II to improve their pulmonary function.
Impaired oxygenation and ventilation during sleep, observed in the majority of individuals
with MPS II, may be a consequence of poor ventilatory reserve in the context of restrictive
pulmonary disease and OSA. Blunted central ventilatory responsiveness is another
consideration, possibly related to body structure as observed in obesity-hypoventilation
syndrome versus a representation of neurologic involvement in MPS [23]. All our subjects
had normal awake serum CO2, suggesting that pulmonary disease was not sufficiently
severe to cause persistent hypercarbia. Sleep-related hypoventilation corresponded to
daytime pulmonary function, which suggests that pulmonary function tests could serve as an
important clinical predictor of the presence of these gas-exchange abnormalities.
As in other syndromes with short stature, accurate interpretation of lung function poses
challenges because parameters in children are typically expressed in percent-predicted based
on height for a given age. Absolute values of FVC and FEV1 showed minimal change with
age, which coincides with lack of physical and chest growth in these subjects. Measures that
are independent of height (FEV1/FVC and RV/TLC) were often abnormal, the latter
correlating with age consistent with disease progression. RV/TLC is a sensitive measure of
lower airway obstruction and air-trapping, whereas FEV1/FVC is more indicative of larger
airway obstruction. Such obstructive disease in MPS can result from GAG deposits in the
lower airway, chronic inflammation, or infection. At our center, patients with MPS often
undergo flexible bronchoscopy at the time of surgical interventions which allows assessment
of the upper and lower airway for GAG deposits. Review of these bronchoscopies has
revealed a high prevalence of widespread deposits, frequently involving the lower airway
[24]. Future studies might employ direct visualization or imaging of the lower airway along
with polysomnography to better characterize these processes.
The relationship of pulmonary function and sleep-related gas exchange may be important
clinically. As observed in our population, pulmonary function testing is difficult to obtain in
many patients with MPS due to neurologic involvement. In these patients, overnight
polysomnography with capnography may be helpful to gauge the degree of pulmonary
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impairment. Conversely, for those patients who are able to perform pulmonary function
reliably, this information may be useful to predict the likelihood of OSA and
hypoventilation. Plethysmography may be beneficial to determine total lung capacity for
suggestion of restrictive disease and RV/TLC, which appears closely related to sleep-related
gas exchange abnormalities.
Systemic ERT is expected to improve somatic manifestations of contractures, restrictive
lung disease and upper airway GAG deposits, but neurologic improvement is not expected
because idursulfase is unable to traverse the blood-brain barrier [25]. The phase II/III
clinical trials of idursulfase showed improvement in lung function and subsequent smaller
studies seemed to indicate improved sleep parameters [26, 27]. Further studies are needed to
more fully understand how ERT may affect sleep among other factors in MPS. Our findings
in an ERT naive population provide important baseline characteristics of sleep and lung
function for comparing patients with MPS II who now receive ERT.
We acknowledge limitations to our study, including that we did not examine patients
longitudinally but rather assessed a cross-sectional cohort. As many aspects of disease
worsen with age, it remains impossible to define contribution of individual factors to sleep
parameters. The relatively small sample size, which is inherent to study of a rare disease,
does not allow subgroup analyses of surgeries and medications. Similarly we cannot exclude
a survivor and floor effect in this cross-sectional group where sicker patients have not
survived to be studied at advanced ages.
According to guidelines by the American Academy of Sleep Medicine, there was not
enough evidence to routinely recommend polysomnography in children with chronic
respiratory diseases, including asthma, cystic fibrosis, and neuromuscular disorders [28].
Subsequently, clinical screening is needed to determine need for polysomnography. In cystic
fibrosis, a progressive childhood disease with primarily obstructive lung disease, a similar
relationship between lung function and sleep-related hypoventilation has been suggested
[29]. As observed in our MPS II population, pulmonary function testing may provide a
useful screening tool to predict the presence of obstructive apnea and gas-exchange
abnormalities.
Acknowledgments
J. M. was the principal investigator for both the MPS II phase I/II enzyme replacement clinical trial and the MPS II
natural history studies at UNC, and has served as a consultant to Shire Human Genetic Therapies, Inc (Cambridge,
MA) for the development of enzyme replacement therapy for the treatment of MPS II. B.V. has received funding





OSA Obstructive sleep apnea
REM Rapid eye movement
SWS Slow-wave sleep
ETCO2 End-tidal carbon dioxide
SpO2 Oxygen saturation per pulse oximetry
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FEV1 Forced expiratory volume in 1 second
FEV1 % Forced expiratory volume in 1 second – percent predicted
FVC Forced vital capacity
FVC % Forced vital capacity – percent predicted
TLC Total lung capacity
RV/TLC Ratio of residual volume to total lung capacity
CPAP Continuous positive airway pressure
BMI Body mass index
ERT Enzyme replacement therapy
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Relationships of age to demographic and clinical characteristics. Age to: A, BMI, B, sleep
efficiency, C, stage I sleep as percentage of total sleep time, D, SWS as percentage of total
sleep time, E, maximum ETCO2, and F, RV/TLC.
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Relationships of sleep-related hypoventilation as measured by increase from baseline
ETCO2 to measures of pulmonary function. A. Increase in ETCO2 to FEV1 %. B, Increase
in ETCO2 to RV/TLC.
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Table I
Subject demographic and clinical characteristics, grouped by study population
ERT trial (n=10) Natural history (n=20) Total (n=30)
Phenotype (attenuated / severe) 10 / 0 8 / 12 18 / 12
Age in years, median (range) 12 (6–21) 8 (3–25) 9 (3–25)
Height percentile* <3% <3% <3%
Weight percentile* 35 % 60 % 52 %
BMI percentile* 89 % 94 % 92 %
Prior PSG† 2 1 3
Positive airway pressure during sleep 3 1 4
Sleep medications 0 3 3
Prior adenotonsillectomy 5 1 6
Prior adenoidectomy alone 1 1 2
Other airway surgery†† 2 0 2
*
Median percentiles are calculated based on United States CDC growth charts, 2000.
†
Prior studies from other centers all revealed OSA. One subject was treated with adenotonsillectomy, the other two were prescribed positive airway
pressure.
††
Other airway surgeries included polypectomy and uvulectomy.
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